UCB buoyed by strong first half; lupus ambitions undented despite PhIII upset
This article was originally published in Scrip
Executive Summary
The mid-sized European pharma company UCB is accelerating its investment in its early-stage portfolio following the continuing sales growth of its three core marketed products, and is also advancing a second potential lupus drug into Phase II trials following disappointing Phase III results reported earlier this week for its first lupus drug epratuzumab.